At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
Voreloxin Injectiondrug
Likely dose
Voreloxin Injection 48 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Voreloxin Injection for Epithelial Ovarian Cancer. Completed, enrolled 183 participants across 20 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpithelial Ovarian Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartDec 2006
Primary CompletionJun 2010
TodayJul 2026
First PostedDec 7, 2006
Enrollment StartDec 20, 2006
Primary CompletionJun 9, 2010
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.6 years ago
Interventions
Voreloxin Injectiondrug
All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.